Spring has finally arrived, particularly for folks down in northeast part of the country. They guys well deserve it!
Tomorrow is another day. We have many many days to June. Little by little is the best way move foreward.
sorry for hearing your loss. It is not a wise thing to sell at this price. Instead, I have sold all my arna and orex sometime ago, and built a sizable position of vvus.
Recently, i have sold puts to further building my shares.
for any honest person, who will know vvus will not go bankrupt for around $300 million cash for many many quarters now, and it will maintain that amount of money for some time in the future.
It all depends on the success of the two products in the market! But at $2.69 a piece and compared to orex and arna, give me a big break.
As for shorts, they are doomed. I have enough patience to see them get ruined!
Which means fungi (with n omitted to avoid yahoo understand so you could not see this post in the first place). It is also means according to everybody's dictionary:
"any of a diverse group of eukaryotic single-celled or multinucleate organisms that live by decomposing and absorbing the organic material in which they grow, comprising the mushrooms, molds, mildews, smuts, rusts, and yeasts, and classified in the kingdom Fungi or, in some classification systems, in the division Fungi (Thallophyta) of the kingdom Plantae."
Today's CLDX news is super good and expected as will be the coming of some similar super good news which may from JUNO, KITE, BLUEBIRD, etc., for all these again and again validate immunotherapy in treating cancers;
There are market for everybody as all are designed to treat a fraction of one or two indications at this time.
Though NWBO is lagging behind CLDX now in terms of enrolment, etc., since its DCVax-L is designed to treat all population as it loads all antigens of a specific patient (not just part of the antigens of a patient), it will be proved to be superior to CLDX, etc, later.
A good scenario is all will be coexist to treat the parts of their intended patients.
Nonetheless, there is likely a best scenario that NWBO will be proven to be superior to treat not only the general patient population but also those specific portions of patients that CLDX and the like are designed to treat.
That's the time when a new standard of care is born.
Remember this concerns only DCVax-L. The potentially more powerful and broader indications treatment vaccine DCVax-D will be much much significant if proven (not intended for today's topic).
BTW, since DCVax-L was so superior judged by Ph1 data, FDA approved its PhII and very quickly approved its transitional directly to Ph3 trial. So FDA will not have any Ph2 data available to give it a breaking through designation (Can FDA bases its decision on data from Ph1?)
Today's market cap for CLDX is more than 2 billion, about 3 billions for JUNO, Kite and Blue compared to NWBO's less than 400 millions.
So all are good!
Did you realize you are too much in that you have lost your last cent of credit. Guess Mr. Mehiel's secretary had nothing to do but file this "nothing new" SEC 13G.
Plus Jerry it is free to file a SEC document, can you also file one "nothing has changed" document to entertain us a bit more instead of constant bashing in this useless YHB?
You get to realize sometime enough is enough unless you count numbers of your useless message to invoice short hedge funds for you hardworking?
i.e., an arm of patients who elect not to have any chemoradiotherapy but only to receive DCVax-L vaccine. The idea and the application of it to FDA must have been for a long time, and it is totally logic to test this since patients will be better off without their immunization system being damaged by chemoradiotherapy, thus making DCVax-L work much better.
If this turns out to be true, it will be a huge positive!
It seems all other possibilities don't make any sense: expanding trial sites doesn't warrant a news release; increasing numbers of patients again for the trial is highly unlikely since memory of the first expansion is still fresh and I don't think FDA has any appetite for that (neither we and the company do); adding another indication to the trial such as ovarian cancer is illogic and against FDA guideline [buzz is an expert on that]...
Okay, back to hibernation.
Which firms are next to upgrade vvus? Maybe after a buyout or partnership deal?
The "million dollar" question or dispute is centered on "since we don't know how many these patients are pseudo or true early pression patients, no one really knows how significant is this data to day:
Really, you guys have woken me up from my hibernation. Those of you who confused should go look up on dictionary of the meaning for median.
IT IS THE TRUE EARLY PROGRESSION PATIENTS WHO HAVE CONTRIBUTED MOST IF NOT ALL TO THAT UNBELIEVABLE 18 MONTHS LONG PFS FOR THE INFORMATION ARM, PERIOD!
In other words, it is truly that the worst patient groups who have a median PFS of 18 months compared to normal and majority of patients who usually only have about 10 months of PFS.
Now I am back to hibernation, and don't wake me up unless share price hits $20.
I will let vvus to run up and bought some nwbo today. Still leave dry power ready in case
The same forces which have shorted now switch to outperform rating, more to come. I am happy as long as vvus price is getting close to its fair value of $10 little by little!
You will be right when you reverse what you have been saying. Move on man to other boards, it will be easy for you to earn message-based commission!
But community college is still the best choice for you!
better than making little commissions for short hedges! And it is free or will be free in more states!